GH Research Plc
(NASDAQ : GHRS)

( )
GHRS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. -0.01%78.320.7%$1640.63m
JNJJohnson & Johnson 0.72%161.260.7%$1027.09m
PFEPfizer Inc. -0.38%41.510.9%$984.93m
ABBVAbbVie, Inc. 0.41%109.361.9%$719.23m
BMYBristol-Myers Squibb Co. 1.11%58.341.0%$691.66m
LLYEli Lilly & Co. 0.55%237.981.1%$629.67m
AZNAstraZeneca Plc 0.92%60.221.0%$377.08m
NVSNovartis AG 0.90%83.340.2%$177.37m
GSKGlaxoSmithKline Plc 0.75%39.010.2%$158.74m
RGENRepligen Corp. -0.61%266.926.8%$129.47m
AVIRAtea Pharmaceuticals, Inc. -2.89%39.280.3%$121.41m
CRVSCorvus Pharmaceuticals, Inc. -3.51%4.950.7%$109.87m
VTRSViatris, Inc. -0.15%13.460.0%$98.18m
NVONovo Nordisk A/S 1.89%102.340.1%$90.55m
RPRXRoyalty Pharma Plc 3.59%38.390.1%$87.06m

Company Profile

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Sch├â┬Ânharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.